Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials

Pulmonary Pharmacology and Therapeutics

Volumn 29, Issue 1, 2014, Pages 80-88

  Zhuo, Guang Ying ^a,b   He, Qing ^c   Xiang Lian, Li ^b   Ya Nan, Yin ^d   Si Te, Feng ^b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Third People's Hospital of Chengdu   (China)

^d SICHUAN UNIVERSITY   (China)

Author keywords

Antibiotic resistance; Azithromycin; Bronchiectasis; Erythromycin; Macrolides

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; PLACEBO; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL DISCOMFORT; ADULT; ADULT DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BRONCHIECTASIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ELECTROCARDIOGRAM; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HEADACHE; HEART ARRHYTHMIA; HUMAN; LONG TERM CARE; LUNG FIBROSIS; LUNG FUNCTION; MACULOPAPULAR RASH; MAINTENANCE THERAPY; META ANALYSIS; MORAXELLA CATARRHALIS; NAUSEA; NON CYSTIC FIBROSIS BRONCHIECTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; VOMITING; LUNG FUNCTION TEST; TIME FACTOR;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MACROLIDES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TIME FACTORS;

EID: 84906936060     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.02.002     Document Type: Article

References (41)

1. Goeminne P., Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010, 86:493-501.
2. Kim C., Kim D.G. Bronchiectasis. Tuberc Respir Dis 2012, 73:249-257.
3. Rademacher J., Welte T. Bronchiectasis - diagnosis and treatment. Dtsch Arzteblatt Int 2011, 108:809-815.
4. Goeminne P.C., Soens J., Scheers H., De Wever W., Dupont L. Effect of macrolide on lung function and computed tomography (CT) score in non-cystic fibrosis bronchiectasis. Acta Clin Belg 2012, 67:338-346.
5. Shoemark A., Ozerovitch L., Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007, 101:1163-1170.
6. Harris J.K., Zemanick E.T. Microbes in bronchiectasis: the forest or the trees?. Am J Respir Crit Care Med 2013, 187:1044-1045.
7. O'Donnell A.E. Bronchiectasis. Chest 2008, 134:815-823.
8. Stafler P., Carr S.B. Non-cystic fibrosis bronchiectasis: its diagnosis and management. Arch Dis Child Educ Pract Ed 2010, 95:73-82.
9. Zoumot Z., Wilson R. Respiratory infection in noncystic fibrosis bronchiectasis. Curr Opin Infect Dis 2010, 23:165-170.
10. Steel H.C., Theron A.J., Cockeran R., Anderson R., Feldman C. Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediat Inflamm 2012, 2012:584262.
11. Zarogoulidis P., Papanas N., Kioumis I., Chatzaki E., Maltezos E., Zarogoulidis K. Macrolides: from invitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol 2012, 68:479-503.
12. Ilowite J., Spiegler P., Kessler H. Pharmacological treatment options for bronchiectasis: focus on antimicrobial and anti-inflammatory agents. Drugs 2009, 69:407-419.
13. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010, 23:590-615.
14. Kudoh S. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med 2004, 117(Suppl.9A):12S-19S.
15. Yousef A.A., Jaffe A. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev 2010, 11:108-114.
16. Anwar G.A., Bourke S.C., Afolabi G., Middleton P., Ward C., Rutherford R.M. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008, 102:1494-1496.
17. Evans D.J., Bara A.I., Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007, CD001392.
18. Malhotra-Kumar S., Lammens C., Coenen S., Van Herck K., Goossens H. Effect ofazithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 2007, 369:482-490.
19. Karlowsky J.A., Lagace-Wiens P.R., Low D.E., Zhanel G.G. Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005. Int J Antimicrob Agents 2009, 34:375-379.
20. Tsang K.W., Ho P.I., Chan K.N., Ip M.S., Lam W.K., Ho C.S., et al. Apilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999, 13:361-364.
21. Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
22. Altenburg J., de Graaff C.S., Stienstra Y., Sloos J.H., van Haren E.H., Koppers R.J., et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAm Med Assoc 2013, 309:1251-1259.
23. Serisier D.J., Martin M.L., McGuckin M.A., Lourie R., Chen A.C., Brain B., et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAm Med Assoc 2013, 309:1260-1267.
24. Jaffe A., Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31:464-473.
25. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
26. Florescu D.F., Murphy P.J., Kalil A.C. Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm Pharmacol Ther 2009, 22:467-472.
27. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004, 125:41S-50S. quiz 1S.
28. Shinkai M., Henke M.O., Rubin B.K. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008, 117:393-405.
29. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?. Drugs 2007, 67:965-974.
30. Diego A.D., Milara J., Martinez-Moragon E., Palop M., Leon M., Cortijo J. Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. Respirology (Carlton, Vic) 2013, 18:1056-1062.
31. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105:946-949.
32. Zuckerman J.M. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 2004, 18:621-649. xi-
33. Martinez-Garcia M.A., Perpina-Tordera M., Roman-Sanchez P., Soler-Cataluna J.J. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005, 128:739-745.
34. Loebinger M.R., Wells A.U., Hansell D.M., Chinyanganya N., Devaraj A., Meister M., et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009, 34:843-849.
35. Martinez-Garcia M.A., Soler-Cataluna J.J., Perpina-Tordera M., Roman-Sanchez P., Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
36. Elizur A., Cannon C.L., Ferkol T.W. Airway inflammation in cystic fibrosis. Chest 2008, 133:489-495.
37. Saiman L., Anstead M., Mayer-Hamblett N., Lands L.C., Kloster M., Hocevar-Trnka J., et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAm Med Assoc 2010, 303:1707-1715.
38. Cai Y., Chai D., Wang R., Bai N., Liang B.B., Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. JAntimicrob Chemother 2011, 66:968-978.
39. Pires dos Santos R., Kuchenbecker R. Azithromycin and the risk of cardiovascular death. NEngl J Med 2012, 367:774-775. author reply 5.
40. Straus S.M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., van der Lei J., de Graeff P.A., et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005, 26:2007-2012.
41. Altenburg J., de Graaff C.S., van der Werf T.S., Boersma W.G. Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respir Int Rev Thorac Dis 2011, 81:75-87.